Active Ingredient History
Sufentanil is a synthetic opioid analgesic. Sufentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Sufentanil may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Sufentanil depresses the respiratory centers, depresses the cough reflex, and constricts the pupils. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Sufentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids open calcium-dependent inwardly rectifying potassium channels (OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability. Sufentanil is used as an analgesic adjunct in anesthesia and as a primary anesthetic drug in procedures requiring assisted ventilation and in the relief of pain. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Pain (approved 1984)
Acetaminophen (Early Phase 1)
Acne Vulgaris (Phase 3)
Acute Pain (Phase 4)
Adenoids (Phase 4)
Adrenal Gland Diseases (Phase 4)
Analgesia (Phase 4)
Analgesia, Epidural (Phase 4)
Analgesia, Patient-Controlled (Phase 4)
Analgesics (Phase 4)
Analgesics, Opioid (Phase 4)
Anemia, Sickle Cell (Phase 3)
Anesthesia (Phase 4)
Anesthesia, Epidural (Phase 4)
Anesthesia, General (Phase 4)
Anesthesia, Local (Phase 3)
Anesthesia, Obstetrical (Phase 3)
Anesthesia, Spinal (Phase 4)
Anxiety (Phase 2)
Aortic Aneurysm (Phase 4)
Aortic Valve Stenosis (Phase 4)
Arterial Occlusive Diseases (Phase 3)
Arteriovenous Malformations (Phase 4)
Arthropathy, Neurogenic (Phase 2/Phase 3)
Arthroplasty (Phase 4)
Arthroscopy (Phase 4)
Asthma (Phase 4)
Back Pain (Phase 3)
Biological Availability (Phase 1)
Brain Injuries (Phase 4)
Breast Neoplasms (Phase 4)
Bronchoscopy (Phase 4)
Buprenorphine (Phase 4)
Carcinoma, Hepatocellular (Phase 4)
Carcinoma, Intraductal, Noninfiltrating (Phase 4)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Catheters (Phase 4)
Cerebral Hemorrhage (Phase 2)
Cesarean Section (Phase 4)
Chemoembolization, Therapeutic (Phase 4)
Chronic Pain (Phase 4)
Cognition Disorders (Phase 4)
Cognitive Aging (Early Phase 1)
Colorectal Surgery (Phase 4)
Conscious Sedation (Phase 4)
Coronary Artery Bypass (Phase 4)
Coronary Disease (Phase 4)
Craniocerebral Trauma (Phase 2)
Delirium (Phase 4)
Depression, Postpartum (Phase 4)
Dexamethasone (Phase 4)
Dexmedetomidine (Phase 4)
Drugs, Investigational (Phase 4)
Drug Therapy (Phase 4)
Electroencephalography (Phase 4)
Emergence Delirium (Phase 4)
Emergencies (Phase 4)
Epigenomics (Phase 4)
Fentanyl (Phase 4)
Fractures, Bone (Phase 4)
Gastrectomy (Phase 4)
General Surgery (Phase 4)
Healthy Volunteers (Phase 4)
Hearing Loss (Phase 1)
Hearing Loss, Noise-Induced (Phase 1)
Hearing Loss, Sensorineural (Phase 1)
Heart Diseases (Phase 4)
Hemodynamics (Phase 4)
Hip Injuries (Phase 2/Phase 3)
Hysteroscopy (Phase 4)
Inflammation (Phase 4)
Infusion Pumps (Phase 4)
Inhalation (Phase 1/Phase 2)
Intensive Care Units (Phase 3)
Intestinal Diseases (Phase 2/Phase 3)
Intestinal Neoplasms (Phase 3)
Intubation, Intratracheal (Phase 2/Phase 3)
Ischemic Attack, Transient (Phase 3)
Ketamine (Phase 3)
Labor, Obstetric (Phase 2/Phase 3)
Labor Pain (Phase 4)
Laparoscopy (Phase 4)
Lidocaine (Phase 3)
Liver Diseases (Phase 2/Phase 3)
Liver Neoplasms (Phase 3)
Morphine (Phase 4)
Myocardium (Phase 2/Phase 3)
Neoplasms (Phase 4)
Nerve Block (Phase 3)
Nociceptive Pain (Phase 1/Phase 2)
Opiate Alkaloids (Phase 1/Phase 2)
Opioid-Related Disorders (Phase 4)
Orthopedic Procedures (Phase 3)
Oxycodone (Phase 1)
Pain (Phase 4)
Pain Management (Phase 3)
Pain, Postoperative (Phase 4)
Pancreatic Diseases (Phase 2/Phase 3)
Pancreatic Neoplasms (Phase 4)
Pancreatitis (Phase 3)
Patient Satisfaction (Phase 4)
Pediatrics (Phase 3)
Pelvic Floor Disorders (Phase 2/Phase 3)
Perfusion (Phase 2/Phase 3)
Perioperative Care (Phase 4)
Pharmacokinetics (Phase 1)
Plasma (Phase 1)
Postoperative Cognitive Complications (Phase 4)
Postoperative Complications (Phase 4)
Postoperative Nausea and Vomiting (Phase 4)
Pregnancy (Phase 4)
Pregnancy Complications (Phase 4)
Pregnant Women (Phase 2)
Premedication (Phase 2/Phase 3)
Prenatal Diagnosis (Phase 2)
Prostatic Neoplasms (Phase 4)
Pulpitis (Phase 2)
Remifentanil (Phase 4)
Respiratory Distress Syndrome (Phase 4)
Scoliosis (Phase 4)
Sleep Disorders, Intrinsic (Phase 4)
Spinal Fusion (Phase 3)
Spinal Injuries (Phase 4)
Stroke (Phase 3)
Sufentanil (Phase 4)
Thoracic Surgery (Phase 4)
Thoracic Surgery, Video-Assisted (Phase 4)
Tonsillitis (Phase 4)
Transsexualism (Phase 3)
Traumatology (Phase 3)
Trigeminal Neuralgia (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue